aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

aTyr Pharma, Inc.NASDAQ: ATYR

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 3.4% from a year ago

Cash & equivalents stood at $10.01M at the end of Q1 FY2026, down 3.4% from a year earlier and down 6.8% from the prior quarter. Over 3 fiscal years it compounded at +2.5% a year.

Context

  • Cash & equivalents amounted to 12.6% of total assets at the end of Q1 FY2026, up 1.9 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -3.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.01M-6.8% QoQ
Last fiscal yearDec 2025
$10.74M-2.8% YoY
Year agoMar 2025
$10.36M-3.4% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.4%——
1 year-2.8%——
3-year CAGR+2.5%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
10.74M USD
Year-over-year change
-2.8%
4-year CAGR
+46.4%

Cash & Equivalents vs competitors

How ATYR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -3.4% is the 7th highest of 8, against a peer median of +56.6%.
  • Cash & equivalents amounts to 12.6% of total assets for ATYR, versus a peer median of 58.0%.
ATYR Competitors
Cash & Equivalents for ATYR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
DTILPrecision BioSciences, Inc.Mar 2026$99.37M USD+28.7%-16.4%69.1%
CAMPCAMP4 Therapeutics CorporationMar 2026$99.21M USD+101.1%—94.1%
UNCYUnicycive Therapeutics, Inc.Mar 2026$37.37M USD+89.0%+300.4%58.0%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$34.06M USD-13.0%+12.0%31.6%
ALXOALX Oncology Holdings Inc.Mar 2026$32.28M USD+56.6%-30.5%18.1%
HYFTMindWalk Holdings Corp.Jan 2026CA$14.18M CAD+9.8%-29.1%61.2%
ATYRaTyr Pharma, Inc.Mar 2026$10.01M USD-3.4%+2.5%12.6%
RLMDRelmada Therapeutics, Inc.Mar 2026$9.78M USD+750.3%-13.5%4.2%
Peer median (excluding ATYR) —+56.6%-14.9%58.0%

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents2.34M9.98M22.54M11.06M10.74M
Short-term Investments105.58M56.17M75.62M61.07M67.94M
Net Receivables435K11.78M2.44M1.74M873K
Inventory00000
Other Current Assets00000
Total Current Assets113.57M80.87M102.99M81.95M80.24M
Property, Plant & Equipment (Net)1.81M11.56M14.05M11.86M10.38M
Goodwill00000
Intangible Assets00000
Long-term Investments00002.24M
Tax Assets00000
Other Non-current Assets158K3.36M3.62M3.02M1.31M
Total Non-current Assets1.97M14.92M17.66M14.88M13.93M
Total Assets115.54M95.79M120.65M96.83M94.16M
Account Payables1.03M3.11M3.53M4.32M3.89M
Short-term Debt00001.47M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00006.81M
Total Current Liabilities6.01M13.86M16.42M14.97M15.15M
Long-term Debt00000
Deferred Tax Liabilities00001.16M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities398K10.64M13.77M12.03M11.73M
Total Liabilities6.41M24.5M30.18M27M26.88M
Common Stock28K29K63K84K98K
Retained Earnings(372.3M)(417.63M)(468.02M)(532.05M)(606.16M)
Accumulated OCI(263K)(433K)(74K)(40K)(8K)
Other Stockholders Equity00000
Minority Interest(175K)(180K)(188K)(187K)(192K)
Total Equity109.13M71.28M90.47M69.83M67.29M
Total Debt1.38M11.53M15.1M13.28M12.03M
Net Debt(958K)1.55M(7.45M)2.23M1.29M

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.